This article was originally published in The Rose Sheet
Modern Health Labs provided adequate substantiation for establishment, safety and performance claims for its Scalp Med Hair Restoration for Men and Women featured in an infomercial and on the company's Web site, Electronic Retailing Self-Regulation Program concludes in a recent Case Reports. ERSP determines there was a reasonable basis for claims hair will "grow back thicker and fuller" with product use and that Scalp Med will "prevent hair loss," "reverse thinning hair" and "re-grow hair." Watchdog group also finds comparative claim "works faster than a hair transplant" was supported. However, ERSP notes statement the formula is the "best product for re-growing hair" communicated a measurable superiority claim that was not supported, and therefore should be modified in future ads. Modern Health Labs responds it will consider ERSP's comments when developing future ads...
You may also be interested in...
Like other hand sanitizer manufacturers, WillSpeed Technology claims its GermBloc “kills 99.99% of germs.” Plaintiffs in a proposed class action filed in Massachusetts federal court allege the claim “grossly overstates” the product’s efficacy, deceiving consumers and endangering them with false confidence.
Keeping Track: US FDA Set For Speed With Approvals Of Inqovy, Rukobia, Dojolvy, Phesgo; Keytruda Loses Chance At AA In HCC
The latest drug development news and highlights from the Pink Sheet’s FDA Performance Tracker.
Syndax CEO also says US FDA’s virtual meetings would benefit from having advisory committee members on camera, which may be a technology challenge.